Company intelligence / Profile preview

CS-Medicines

Mannheim, Baden-Württemberg, Germany

Ownership: Private
Development stage: Other

Overview

CS-Medicines is a clinical-stage biotechnology company dedicated to developing novel cannabinoid-based therapies for autoimmune and inflammatory diseases. The company's lead program, CSM-001, is a potent and selective synthetic cannabinoid receptor 2 (CB2) agonist designed to provide anti-inflammatory effects without the psychoactive properties associated with CB1 activation. CS-Medicines focuses on dermatological conditions such as psoriasis and atopic dermatitis, aiming to provide safer and more effective alternatives to current standard-of-care treatments. The company leverages its expertise in cannabinoid pharmacology to advance a pipeline of small molecule candidates through clinical development.

Therapeutic areas: ImmunologyDermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on CS-Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS-Medicines.

Explore the full profile